Clinical Trials

Cancer-focused biosciences company updates U.S. NCI-sponsored clinical trials

Published in Cardiovascular Week, September 12th, 2005

Kosan Biosciences Incorporated (KOSN) announced that it was advised on August 12, 2005, that the Division of Cancer Treatment and Diagnosis at the U.S. National Cancer Institute (NCI) intends to amend the protocols for the NCI's 17-AAG and DMAG clinical trials.

The amendments are being made in response to 5 patients that showed EKG changes without clinically significant consequences after infusion of 17-AAG.

With the amended protocols, clinical investigators will obtain electrocardiograms prior to treatment with 17-AAG or DMAG and after infusion in the initial cycle of therapy. The protocol amendments will also exclude patients with certain histories...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Week

Source: Cardiovascular Week (2005-09-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry